Cytokinetics (CYTK) Prices 10M Share Offering at $27.5/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises in broad rebound; yields push markets towards weekly declines
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
- SpaceX shares fall as second lockup period ends
Cytokinetics Announces Pricing of Public Offering of Common Stock
July 20, 2021 11:15 PM EDTSOUTH SAN FRANCISCO, Calif., July 20, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a price to the public of $27.50 per share, before underwriting discounts and commissions. The gross proceeds to Cytokinetics from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Cytokinetics, are expected to be $275 million. The offering is expected to close on July 23, 2021, subject to customary closing conditions. Additionally, Cytokinetics has granted the underwriters a 30-day option to purchase... More
